Skip to main content

Search

About
Case studies
News
- Upcoming events
- Past events
- Current projects
  - Translational Fund Projects
- Past projects
For the public

SEARCH

Home
News
Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab

Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab

Studying brain scan images.jpg

15th April 2021

The phase II trial results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer’s disease and also slowed the accumulation of tau across key brain regions in patients.

https://www.alzint.org/news/eli-lilly-presents-results-for-phase-2-trailblazer-alz-trial-for-donanemab

This website is licensed under a CC-BY licence | UK SPINE 2024

Accessibility Privacy notice

Funded by

Connect with us

Twitter YouTube

Funded by